Therapeutic strategies for microsatellite expansion diseases using RNA-targeting CRISPR/Cas
使用 RNA 靶向 CRISPR/Cas 治疗微卫星扩增疾病的策略
基本信息
- 批准号:10171924
- 负责人:
- 金额:$ 59.05万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-09-22 至 2022-05-31
- 项目状态:已结题
- 来源:
- 关键词:3&apos Untranslated RegionsAdoptedAdultAffectAlternative SplicingAnimal ModelAutopsyBCAR1 geneBindingBiological MarkersBiopsyC9ORF72Cell ExtractsCell modelCellsCharacteristicsChemicalsCleaved cellClinicalClustered Regularly Interspaced Short Palindromic RepeatsDNADataDefectDependovirusDevelopmentDiseaseEndoribonucleasesEventFoundationsGenesGenetic TranscriptionGoalsGuide RNAHealthHumanHuntington DiseaseImageIn VitroInheritedIntronsKnock-in MouseLeadLinkMammalian CellMeasuresMediatingMessenger RNAMicrosatellite InstabilityMicrosatellite RepeatsModelingModificationMovementMusMuscleMuscle FibersMuscular DystrophiesMyoblastsMyotonic DystrophyNeuromuscular DiseasesNuclear RNAOligonucleotidesPathogenesisPatientsPolyadenylationProteinsRNARNA BindingRNA DegradationRNA ProcessingRNA-Binding ProteinsSafetySerotypingSpecificitySystemTechnologyTestingTherapeuticTimeTissuesToxic effectTransduction GeneTransgenesTreatment EfficacyViral Genomeadeno-associated viral vectorbasebiomarker panelefficacy evaluationefficacy studygene therapygenome editinghuman diseasehuman subjectimmunogenicityin vivomouse modelnovelparticipant safetypre-clinicalprognosticprogramsrecruitsafety studystress granulesuccesstherapeutic developmenttherapeutic evaluationtherapeutic targettherapy developmenttranscriptome sequencing
项目摘要
Project Summary
The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas system has become widely
adopted for DNA recognition, enabling applications such as genome editing and recruiting effector proteins to
DNA to affect transcription or enable imaging. Recently in Nelles et al, Cell, 2016, we showed that with
modifications, catalytically dead Cas9 with a modified oligonucleotide containing the PAM recognition
sequence is able to bind specific mRNAs in living mammalian cells and is able to track their movement,
opening up the potential for many RNA applications of Cas proteins. In this proposal, we aim at developing a
adeno-associated virus (AAV)-based therapeutic strategy for myotonic dystrophy, a microsatellite expansion
disease characterized by expanded CTG repeats, using RNA-targeting CRISPR/Cas9 (RCas9). We will
perform in vivo safety and efficacy studies of our AAV-based therapy and evaluate the hypothesis that
alternative RNA processing biomarkers are reliable for measuring treatment efficacy of RCas9 in myotonic
dystrophy. If successful, we will have taken a significant step forward in developing a treatment for a class of
microsatellite expansion diseases.!
项目概要
成簇规则间隔短回文重复序列 (CRISPR)/Cas 系统已得到广泛应用
用于 DNA 识别,使基因组编辑和招募效应蛋白等应用成为可能
DNA 影响转录或实现成像。最近,在 Nelles 等人的《Cell》,2016 年中,我们证明了
修饰,带有包含 PAM 识别的修饰寡核苷酸的催化死亡 Cas9
序列能够结合活体哺乳动物细胞中的特定 mRNA,并能够追踪它们的运动,
为 Cas 蛋白的许多 RNA 应用开辟了潜力。在本提案中,我们的目标是开发一个
基于腺相关病毒(AAV)的强直性肌营养不良治疗策略,微卫星扩展
使用 RNA 靶向 CRISPR/Cas9 (RCas9) 来扩展 CTG 重复序列为特征的疾病。我们将
对我们基于 AAV 的疗法进行体内安全性和有效性研究,并评估以下假设:
替代 RNA 加工生物标志物可可靠地测量 RCas9 在肌强直中的治疗效果
营养不良。如果成功的话,我们将在开发针对一类疾病的治疗方法方面迈出重要一步。
微卫星扩张疾病。!
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(1)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MAURICE SCOTT SWANSON其他文献
MAURICE SCOTT SWANSON的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MAURICE SCOTT SWANSON', 18)}}的其他基金
Therapeutic strategies for microsatellite expansion diseases using RNA targeting
利用 RNA 靶向治疗微卫星扩增疾病的策略
- 批准号:
10588064 - 财政年份:2017
- 资助金额:
$ 59.05万 - 项目类别:
MECHANISMS OF RNA-MEDIATED CNS PATHOGENESIS IN MYOTONIC DYSTOPHY
RNA介导的强直性肌营养不良中枢神经系统发病机制
- 批准号:
8609101 - 财政年份:2008
- 资助金额:
$ 59.05万 - 项目类别:
MECHANISMS OF RNA-MEDIATED CNS PATHOGENESIS IN MYOTONIC DYSTOPHY
RNA介导的强直性肌营养不良中枢神经系统发病机制
- 批准号:
9105456 - 财政年份:2008
- 资助金额:
$ 59.05万 - 项目类别:
MECHANISMS OF RNA-MEDIATED CNS PATHOGENESIS IN MYOTONIC DYSTOPHY
RNA介导的强直性肌营养不良中枢神经系统发病机制
- 批准号:
8739678 - 财政年份:2008
- 资助金额:
$ 59.05万 - 项目类别:
Preclinical models, biomarkers, and therapy for myotonic dystrophy type 1
1 型强直性肌营养不良的临床前模型、生物标志物和治疗
- 批准号:
10021453 - 财政年份:2003
- 资助金额:
$ 59.05万 - 项目类别:
Preclinical models, biomarkers, and therapy for myotonic dystrophy type 1
1 型强直性肌营养不良的临床前模型、生物标志物和治疗
- 批准号:
10480097 - 财政年份:2003
- 资助金额:
$ 59.05万 - 项目类别:
MOUSE MUSCLEBLIND MODEL FOR MYOTONIC DYSTROPHY
强直性肌营养不良小鼠肌盲模型
- 批准号:
6824697 - 财政年份:2003
- 资助金额:
$ 59.05万 - 项目类别:
Preclinical models, biomarkers, and therapy for myotonic dystrophy type 1
1 型强直性肌营养不良的临床前模型、生物标志物和治疗
- 批准号:
10237267 - 财政年份:2003
- 资助金额:
$ 59.05万 - 项目类别:
相似海外基金
Role of miR-195 in Chemo-Resistant Ovarian Cancer
miR-195 在化疗耐药性卵巢癌中的作用
- 批准号:
10640540 - 财政年份:2023
- 资助金额:
$ 59.05万 - 项目类别:
Translational Regulation of SARS-CoV-2 in response to viral S protein-induced signaling
SARS-CoV-2 响应病毒 S 蛋白诱导信号传导的翻译调控
- 批准号:
10721101 - 财政年份:2023
- 资助金额:
$ 59.05万 - 项目类别:
New cell biology tools to study myelin development, dynamics, and disease
研究髓磷脂发育、动力学和疾病的新细胞生物学工具
- 批准号:
10649184 - 财政年份:2023
- 资助金额:
$ 59.05万 - 项目类别:
Viral Noncoding RNAs and Cell Transformation
病毒非编码 RNA 和细胞转化
- 批准号:
10364830 - 财政年份:2022
- 资助金额:
$ 59.05万 - 项目类别:
Viral Noncoding RNAs and Cell Transformation
病毒非编码 RNA 和细胞转化
- 批准号:
10553131 - 财政年份:2022
- 资助金额:
$ 59.05万 - 项目类别: